# US 2002/0119991 A1 · Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0119991 A1
- Document ID: US20020119991A1
- Status: Published application
- Kind: A1
- Application number: 09/965,766
- Filed: 2001-09-28
- Published: 2002-08-29
- Earliest claimed: 2000-10-14
- Assignees: Boehringer Ingelheim Pharma GmbH & Co. KG
- Inventors: Helmut Meissner; Gerd Morschhaeuser; Michael Paul Pieper; Gerald Pohl; Richard Reichl; Georg Speck
- Web page: https://patentgrep.com/patent/US20020119991A1

## CPC

- C07D 451/10: acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
- A61P 11/06: Antiasthmatics
- A61P 13/06: Anti-spasmodics
- C07D 451/14: containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A compound of formula 1 1 wherein: A is a group selected from 2 X− is an anion with a single negative charge; R1 and R2 are each independently a C1-C4-alkyl optionally substituted with hydroxy or halogen; and R3, R4, R5, R6, R7, and R8 are each independently hydrogen, C1-C4-alkyl, C1-C4-alkyloxy, hydroxy, CF3, CN, NO2, or halogen, with the proviso that at least one of the groups R3, R4, R5, R6, R7, and R8 is not hydrogen, processes for preparing these compounds, pharmaceutical compositions containing these compounds, and their use as pharmaceutical compositions.

## Claims

### Claim 1

A compound of formula 1
62
wherein:
A is a group selected from
63
X− is an anion with a single negative charge;
R1 and R2 are each independently a C1-C4-alkyl optionally substituted with hydroxy or halogen; and
R3, R4, R5, R6, R7, and R8 are each independently hydrogen, C1-C4-alkyl, C1-C4-alkyloxy, hydroxy, CF3, CN, NO2, or halogen,
with the proviso that at least one of the groups R3, R4, R5, R6, R7, and R8 is not hydrogen.

### Claim 2 (depends on 1)

The compounds of formula 1 according to claim 1, wherein:
X− is an anion selected from the group consisting of chloride, bromide, methylsulfate, 4-toluenesulfonate, and methanesulfonate;
R1 and R2 are each independently a group selected from the group consisting of methyl, ethyl, n-propyl, and isopropyl, each optionally substituted by hydroxy or fluorine; and
R3, R4, R5, R6, R7, and R8 are each independently hydrogen, methyl, ethyl, methyloxy, ethyloxy, hydroxy, fluorine, chlorine, bromine, CN, CF3, or NO2.

### Claim 3 (depends on 1)

The compound of formula 1 according to claim 1, wherein:
X− is bromide;
R1 and R2 are each independently methyl or ethyl; and
R3, R4, R5, R6, R7, and R8 are each independently hydrogen, methyl, methyloxy, fluorine, chlorine, or bromine.

### Claim 4 (depends on 3)

The compound of formula 1 according to claim 3, wherein:
R3, R4, R5, R6, R7, and R8 are each independently hydrogen, fluorine, chlorine, or bromine.

### Claim 5 (depends on 4)

The compound of formula 1 according to claim 4, wherein:
A is a group selected from
64

### Claim 6 (depends on 5)

The compound of formula 1 according to claim 5, wherein:
R1 and R2 are each methyl; and
R3, R4, R5, R6, R7, and R8 are each independently hydrogen or fluorine.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising a compound of formula 1 according to claim 1 and a pharmaceutically acceptable excipient and/or carrier.

### Claim 8 (depends on 2)

A pharmaceutical composition comprising a compound of formula 1 according to claim 2 and a pharmaceutically acceptable excipient and/or carrier.

### Claim 9 (depends on 3)

A pharmaceutical composition comprising a compound of formula 1 according to claim 3 and a pharmaceutically acceptable excipient and/or carrier.

### Claim 10 (depends on 4)

A pharmaceutical composition comprising a compound of formula 1 according to claim 4 and a pharmaceutically acceptable excipient and/or carrier.

### Claim 11 (depends on 5)

A pharmaceutical composition comprising a compound of formula 1 according to claim 5 and a pharmaceutically acceptable excipient and/or carrier.

### Claim 12 (depends on 6)

A pharmaceutical composition comprising a compound of formula 1 according to claim 6 and a pharmaceutically acceptable excipient and/or carrier.

### Claim 13 (depends on 7)

The pharmaceutical composition according to claim 7, further comprising an additional active substance selected from the group consisting of betamimetics, antiallergic agents, PAF-antagonists, leukotriene-antagonists, and steroids.

### Claim 14 (depends on 8)

The pharmaceutical composition according to claim 8, further comprising an additional active substance selected from the group consisting of betamimetics, antiallergic agents, PAF-antagonists, leukotriene-antagonists, and steroids.

### Claim 15 (depends on 9)

The pharmaceutical composition according to claim 9, further comprising an additional active substance selected from the group consisting of betamimetics, antiallergic agents, PAF-antagonists, leukotriene-antagonists, and steroids.

### Claim 16 (depends on 10)

The pharmaceutical composition according to claim 10, further comprising an additional active substance selected from the group consisting of betamimetics, antiallergic agents, PAF-antagonists, leukotriene-antagonists, and steroids.

### Claim 17 (depends on 11)

The pharmaceutical composition according to claim 11, further comprising an additional active substance selected from the group consisting of betamimetics, antiallergic agents, PAF-antagonists, leukotriene-antagonists, and steroids.

### Claim 18 (depends on 12)

The pharmaceutical composition according to claim 12, further comprising an additional active substance selected from the group consisting of betamimetics, antiallergic agents, PAF-antagonists, leukotriene-antagonists, and steroids.

### Claim 19 (depends on 1)

A method of treating diseases in which anticholinergics may provide a therapeutic benefit, comprising administering to a host in need of such treatment a compound of formula 1 according to claim 1.

### Claim 20 (depends on 2)

A method of treating diseases in which anticholinergics may provide a therapeutic benefit, comprising administering to a host in need of such treatment a compound of formula 1 according to claim 2.

### Claim 21 (depends on 3)

A method of treating diseases in which anticholinergics may provide a therapeutic benefit, comprising administering to a host in need of such treatment a compound of formula 1 according to claim 3.

### Claim 22 (depends on 4)

A method of treating diseases in which anticholinergics may provide a therapeutic benefit, comprising administering to a host in need of such treatment a compound of formula 1 according to claim 4.

### Claim 23 (depends on 5)

A method of treating diseases in which anticholinergics may provide a therapeutic benefit, comprising administering to a host in need of such treatment a compound of formula 1 according to claim 5.

### Claim 24 (depends on 6)

A method of treating diseases in which anticholinergics may provide a therapeutic benefit, comprising administering to a host in need of such treatment a compound of formula 1 according to claim 6.

### Claim 25 (depends on 1)

A method of treating asthma, COPD, vagally induced sinus bradycardia, heart rhythm disorders, spasms in the gastrointestinal tract, spasms in the urinary tract, or menstrual disorders, comprising administering to a host in need of such treatment a compound of formula 1 according to claim 1.

### Claim 26 (depends on 2)

A method of treating asthma, COPD, vagally induced sinus bradycardia, heart rhythm disorders, spasms in the gastrointestinal tract, spasms in the urinary tract, or menstrual disorders, comprising administering to a host in need of such treatment a compound of formula 1 according to claim 2.

### Claim 27 (depends on 3)

A method of treating asthma, COPD, vagally induced sinus bradycardia, heart rhythm disorders, spasms in the gastrointestinal tract, spasms in the urinary tract, or menstrual disorders, comprising administering to a host in need of such treatment a compound of formula 1 according to claim 3.

### Claim 28 (depends on 4)

A method of treating asthma, COPD, vagally induced sinus bradycardia, heart rhythm disorders, spasms in the gastrointestinal tract, spasms in the urinary tract, or menstrual disorders, comprising administering to a host in need of such treatment a compound of formula 1 according to claim 4.

### Claim 29 (depends on 5)

A method of treating asthma, COPD, vagally induced sinus bradycardia, heart rhythm disorders, spasms in the gastrointestinal tract, spasms in the urinary tract, or menstrual disorders, comprising administering to a host in need of such treatment a compound of formula 1 according to claim 5.

### Claim 30 (depends on 6)

A method of treating asthma, COPD, vagally induced sinus bradycardia, heart rhythm disorders, spasms in the gastrointestinal tract, spasms in the urinary tract, or menstrual disorders, comprising administering to a host in need of such treatment a compound of formula 1 according to claim 6.

### Claim 31

A compound of formula 4
65
wherein:
A is a group selected from
66
R1 is a C1-C4-alkyl optionally substituted with hydroxy or halogen; and
R3, R4, R5, R6, R7, and R8 are each independently hydrogen, C1-C4-alkyl, C1-C4-alkyloxy, hydroxy, CF3, CN, NO2, or halogen,
with the proviso that at least one of the groups R3, R4, R5, R6, R7, and R8 is not hydrogen.

### Claim 32 (depends on 31)

The compound of formula 4 according to claim 31, wherein:
R1 is a group selected from the group consisting of methyl, ethyl, n-propyl, and isopropyl, each optionally substituted by hydroxy or fluorine;
R3, R4, R5, R6, R7, and R8 are each independently hydrogen, methyl, ethyl, methyloxy, ethyloxy, hydroxy, fluorine, chlorine, bromine, CN, CF3, or NO2.

### Claim 33 (depends on 31)

The compound of formula 4 according to claim 31, wherein:
R1 is methyl or ethyl; and
R3, R4, R5, R6, R7, and R8 are each independently hydrogen, methyl, methyloxy, fluorine, chlorine, or bromine.

### Claim 34 (depends on 33)

The compound of formula 4 according to claim 33, wherein:
R3, R4, R5, R6, R7, and R8 are each independently hydrogen, fluorine, chlorine, or bromine.

### Claim 35 (depends on 31)

The compound of formula 4 according to claim 31, wherein:
R3, R4, R5, R6, R7, and R8 are each independently hydrogen or fluorine.

### Claim 36

A compound of formula 3
67
wherein:
R is C1-C4-alkyl; and
R3, R4, R5, R6, R7, and R8 are each independently hydrogen, C1-C4-alkyl, C1-C4-alkyloxy, hydroxy, CF3, CN, NO2, or halogen,
with the proviso that at least one of the groups R3, R4, R5, R6, R7, and R8 is not hydrogen.

### Claim 37 (depends on 36)

The compound of formula 3 according to claim 36, wherein:
R3, R4, R5, R6, R7, and R8 are each independently hydrogen, methyl, ethyl, methyloxy, ethyloxy, hydroxy, fluorine, chlorine, bromine, CN, CF3, or NO2.

### Claim 38 (depends on 36)

The compound of formula 3 according to claim 36, wherein:
R3, R4, R5, R6, R7, and R8 are each independently hydrogen, methyl, methyloxy, fluorine, chlorine, or bromine.

### Claim 39 (depends on 36)

The compound of formula 3 according to claim 36, wherein:
R3, R4, R5, R6, R7, and R8 are each independently hydrogen, fluorine, chlorine, or bromine.

### Claim 40 (depends on 36)

The compound of formula 3 according to claim 36, wherein:
R3, R4, R5, R6, R7, and R8 are each independently hydrogen or fluorine.
